Blood stem cell editing could provide the answer for sickle cell anemia
Using the CRISPR-Cas9 system, researchers have successfully shown that the clinical symptoms of sickle cell anemia and beta-thalassemia can be reversed by targeting CD90 stem cells.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>